We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Votes Down Amylyx Pharmaceuticals’ ALS Drug Candidate
FDA Advisory Panel Votes Down Amylyx Pharmaceuticals’ ALS Drug Candidate
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee yesterday declined by a vote of 6-4 to recommend approval of Amylyx Pharmaceuticals’ AMX0035, a drug intended to treat amyotrophic lateral sclerosis (ALS).